FRX News 95.12 06/12/2014 04:56:29 Forest Laboratories (FRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Forest Laboratories (FRX) 95.12 $FRX

Forest Laboratories plans to continue marketing both NAMENDA TABLETS and once-daily NAMENDA XR up to autumn of 2014
M2 - Wed Jun 11, 7:12AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Tuesday that it will continue to market both its NAMENDA (memantine HCl) 5 mg and 10 mg tablets and once-daily NAMENDA XR (memantine HCl) extended-release capsules through to the the autumn of this year.

Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.

Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA(R) TABLETS and Once-Daily NAMENDA XR(R) Into the Fall of 2014
Business Wire - Tue Jun 10, 3:01PM CDT
-- Initiatives to Ensure Robust and Reliable Product Supply Progressing--

Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.

2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain

Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations" to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company" today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free.

Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...

Active Stocks Technical Coverage -- Research on Forest Laboratories, NII Holdings, Endo Intl., and Aramark
PR Newswire - Mon Jun 02, 6:40AM CDT
The trading session on Friday, May 30, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,717.17, up 0.11% and the NASDAQ Composite closed at 4,242.62, down 0.13%. The S&P 500 finished the day 0.18% higher at 1,923.57. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), NII Holdings Inc. (NASDAQ: NIHD), Endo International PLC (NASDAQ: ENDP) and Aramark (NYSE: ARMK). Free technical research on FRX, NIHD, ENDP and ARMK can be downloaded upon signing up at:

Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The  Science Translational Medicine  journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories  under the brand name Celexa, as a potential way to help slow down the development of...

Forest Laboratories, Inc. Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
Business Wire - Fri May 30, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension.

Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...

Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics
PR Newswire - Tue May 27, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.

Research and Markets: Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
Business Wire - Tue May 27, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdgs5q/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - Tue May 27, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Fri May 23, 1:01PM CDT
Levi & Korsinsky reminds investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.

Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.

SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc.
Business Wire - Thu May 22, 2:39PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (NasdaqGS: FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders.

Research and Markets: Global Neuropathic Pain Report 2014: Grnenthal's Cebranopadol - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 11:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q53s8z/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 29

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 97

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 181

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 74

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 112

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 5

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading

Top 5 Most Recently Viewed Articles

Movable Ink Boosts AI Marketing Strategies with Global Expansion

Updated Category News Views 165

Movable Ink Expands its AI Marketing Solutions Across Europe Movable Ink, a leader in AI-powered personalisation, has significantly boosted its presence in Europe. The company’s innovative approach, termed the Autonomous Marketing strategy, is proving to reshape the marketing landscape. Now, with the launch of its sophisticated Da Vinci product, Movable Ink is setting a...

Continue Reading
Crypto Market Update: Election Impact on Bitcoin and Ethereum

Updated Category News Views 110

Market Movements Amid Election Uncertainty In recent days, leading cryptocurrencies have experienced a noticeable pullback. The shifts in market sentiment appear closely linked to the political atmosphere, particularly surrounding presidential election predictions. As the likelihood of Donald Trump's election victory declined, key cryptocurrencies like Bitcoin and...

Continue Reading
Festi hf. Receives Non-Binding Offers for Olíudreifing ehf.

Updated Category News Views 101

Festi hf. Receives Non-Binding Offers for Olíudreifing ehf. Festi hf. has recently announced the progress concerning Olíudreifing ehf. which is a crucial infrastructure entity specializing in fuel storage and distribution in Iceland. After initiating the sales process on September 26, 2024, the company has now received non-binding offers for all outstanding shares in...

Continue Reading
Canadian Solar Plans US$200 Million Convertible Notes Offering

Updated Category News Views 141

Canadian Solar Announces Offering of Convertible Senior Notes Canadian Solar Inc. (NASDAQ: CSIQ) has recently disclosed plans for the proposed offering of US$200 million in convertible senior notes due 2031. This offering is contingent upon market conditions and other factors. The convertible notes are set to be offered and sold privately to qualified institutional...

Continue Reading
HPQ Silicon Achieves Milestone with First Battery Cell Shipments

Updated Category News Views 185

HPQ Silicon's Exciting Development in Battery Technology HPQ Silicon Inc. (“HPQ”) is thrilled to announce that it has successfully completed and shipped its first industrial batches of high-performance lithium-ion battery cells. Manufactured using their innovative GEN3 silicon-based anode material, these initial cells, which come in the 18650 and 21700 formats under...

Continue Reading